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Pediatric chronic kidney disease (CKD)
• The prevalence of pediatric CKD is rising and is associated with
significant morbidities
• Progression to end-stage-renal disease (ESRD)
• Cardiovascular disease
• Poor developmental and neurocognitive outcomes

• Different etiologies have distinct clinical features, but less is know
regarding biochemical pathophysiology
• Limited ability to progression to ESRD
• Limited targeted therapies for pediatric CKD

Metabolomics
• Metabolomics is the
study of circulating
small molecules that
are metabolism
intermediates
• High dimensional –
omics data poses
challenges to traditional
biostatistics

Machine learning (ML)

Input data

Machine learning

Think of metabolites as
individual pixels that form a
composite matrix

Mathematical algorithms
examine the composite and look
for patterns among the
individual pixels

Classification/regression
task
Is this a cat?
Are there FSGS metabolite
patterns that give insight
to pathomechanism?

Hypotheses
• Different pediatric CKD etiologies will be associated with distinct
metabolomic profiles: focal segmental glomerular sclerosis (FSGS),
obstructive uropathy, reflux nephropathy, and the
aplasia/dysplasia/hypoplasia spectrum
• Machine learning models can be successfully trained to recognized
CKD etiology based on metabolomic differences
• Applying ML in conjunction with traditional biostatistics will improve
clinical insight gained than either approach alone

The Chronic Kidney Disease in Children (CKiD) study

Other
non-glomerular
Reflux
nephropathy
12%

Other
glomerular
FSGS 9%

Aplasia/
Dysplasia/
Hypoplasia
Obstructive
uropathy 17% 16%

• Largest longitudinal cohort of
pediatric CKD in North America
• Enrolled children aged 1-16
years with estimated GFR 3090ml/min/1.73m2
• 702 participants with 842
named metabolites

Limitations of traditional
biostatistics in metabolomics
• High number of input metabolites
• Metabolites are highly interrelated,
not independent variables
• Flawed significance designations

• Limited inferences from a very rich
data source

Application of ML tools
• Feature selection:
• Lasso penalized logistic regression
• Multiple approaches to detect
signals/patterns:
• Logistic regression, support vector
machine, random forest, extreme
gradient boosting

Results: implicated metabolites

Key question:

How do we know our ML models are actually
detecting metabolite signals for CKD etiology
classification?

What can we learn about potential
therapeutics?

Intervention

•

Does sphingomyelin
dysmetabolism induce FSGS
pathology?

•

•

Sphingomyelin
metabolites have been
shown to induce free
radical damage in the
kidney
Abnormal sphingomyelin
deposition implicated in
HIV-related kidney &
brain disease

Rituximab has been shown to alter
sphingomyelin levels and associated
with disease remission

Sphingomyelin
dysmetabolism

?

Is sphingomyelin
dysmetabolism secondary to
primary FSGS?

•

FSGS
pathophysiology

•

Dyslipidemia has been
characterized in CKD
patients
Unclear therapeutic
benefits of lipopheresis
in pediatric nephrotic
syndrome

Conclusions
• Different pediatric CKD etiologies are associated with distinct
metabolomic profiles
• Machine learning models can be successfully trained on pediatric
metabolomics data
• Machine learning can be used as pattern-recognition tools to
augment traditional biostatistics to gain improved clinical insight
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Supplemental

Data analysis: challenges
• Useful to think about challenges related to data-analysis in relation to
the 3 framing topics
Pediatric CKD

Metabolomics

Machine learning

Unbalanced data: relatively
low number of test cases
versus controls based on CKD
etiology

Wide data: number of
metabolites > number of study
participants

Interpretability:
Unfamiliar output compared
to established biostatistics

Metabolites are not
independent variables, have
significant interactions with
other metabolites

How to determine if model
was successfully trained

Differences in participant
characteristics based on CKD
etiology

How to designate a significant
metabolite

Table 1

Feature selection:
Lasso penalized logistic regression

Machine learning algorithms
Support vector machine

Random forest

Plots participants to high dimensional
space based on all input metabolites,
then determines optimal hyperplace
to separate classifications

Aggregated tree model in which a
random number of metabolites are
sampled at each branch point to
perform classification

Extreme gradient
boosting
Aggregated regression models
applied in sequence optimized
for reduce previous
misclassification error

Training models
Repeat x10

Total CKiD Cohort

80% training set

20% validation set

Models trained with repeated
k-fold cross validation

Evaluated performance with
receiver-operator & precisionrecall area-under-the-curve

Determined feature weighting

ML performance evaluation metrics
F-1 score

• Harmonic mean of precision & recall

Matthews correlation coefficient

• ROC-AUC can be artificially inflated
with negatively skewed data in ML

• Includes true negative predictions

Results:

implicated metabolites

• FSGS: sphingomyelin &
plasmalogen
metabolites
• Obstructive uropathy:
histidine metabolites

Key questions:
Does feature selection improve
ML performance and increase our
confidence in the signals
detected?
Does a Lasso feature selection
approach significantly improve
ML performance or alter the
signals detected compared to a
traditional biostatistics feature
selection approach?

